February 27, 2025 How the House’s Budget Plan Sets the Stage for a Fiscal Showdown
Tesla: Capturing Opportunity in a Contrarian Market
Microsoft: Resilient Amid Sell-Off, 'Buy' Stance Reaffirmed
3M: Valuation Challenges Amidst Limited Growth Prospects
March 12, 2025 Features of exchanging USDC ERC20 to Bank Transfer
February 19, 2025 Why Stock Caps Matter When Building a Diversified Portfolio
February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024
January 21, 2025 Trading Stocks With AI: A Modern Approach
January 21, 2025 Bitcoin Is Great, but Here Are 3 Altcoins Worth Considering in 2025
AN2 Therapeutics (ANTX) stock forecast for 2025
Updated: March 2, 2025 (12:46)
Sector: HealthcareThe share price of AN2 Therapeutics, Inc. (ANTX) now
50/200 Day Moving Average: $1.231 / $1.524
This figure corresponds to the Average Price over the previous 50/200 days. For AN2 Therapeutics stocks, the 50-day moving average is the resistance level today.
For AN2 Therapeutics stocks, the 200-day moving average is the resistance level today.
Are you interested in AN2 Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the AN2 Therapeutics stock price in 2025. How much will one AN2 Therapeutics share be worth in 2025? Is it worth taking profit / loss on ANTX stock now or waiting? What are analysts' forecasts for AN2 Therapeutics stock?
We forecast AN2 Therapeutics stock performance using neural networks based on historical data on ANTX stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.
AN2 Therapeutics, Inc. stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for AN2 Therapeutics analysts is $2.667. Today 200 Day Moving Average is the resistance level (1.524 $). 50 Day Moving Average is the resistance level (1.231 $).
Historical and forecast chart of AN2 Therapeutics, Inc. stock
The chart below shows the historical price of AN2 Therapeutics stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the ANTX stock price can be found in the table below.
AN2 is developing treatments for rare, chronic, and serious infectious diseases. Its initial product candidate is epetraborole, a once-daily oral drug that aims to treat chronic nontuberculous mycobacterial lung disease.
The biotech is the second company to open for trading in March. The first was Akanda (ticker: AKAN), a medical-cannabis company, which listed its shares on March 15, soaring 163% in its debut. Akanda stock is down about 18% from the $10.50 first-day closing price but still up 116% from the $4 IPO price.
AN2 Therapeutics (ANTX) Forecast for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Apr | 1.17 | 1.13 | 1.24 | 9.13 % |
| May | 1.20 | 1.12 | 1.23 | 8.48 % |
| Jun | 1.16 | 1.10 | 1.24 | 10.90 % |
| Jul | 1.17 | 1.11 | 1.25 | 11.15 % |
| Aug | 1.10 | 1.03 | 1.12 | 7.87 % |
| Sep | 1.06 | 1.01 | 1.11 | 9.26 % |
| Oct | 1.05 | 0.98 | 1.10 | 10.48 % |
| Nov | 1.08 | 1.03 | 1.14 | 9.72 % |
| Dec | 1.06 | 1.02 | 1.11 | 8.12 % |
AN2 Therapeutics information and performance
1800 EL CAMINO REAL, SUITE D, MENLO PARK, CA, US
Market capitalization of the AN2 Therapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ANTX shares in the company outstanding by the market price of one share.
EBITDA of AN2 Therapeutics is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
AN2 Therapeutics price target for 2025 by month
Target values for the price of one AN2 Therapeutics share for Apr 2025.
In Apr, the Positive dynamics for AN2 Therapeutics, Inc. shares will prevail with possible monthly volatility of 9.126% volatility is expected.
Pessimistic target level: 1.13
Optimistic target level: 1.24
Target values for the price of one AN2 Therapeutics share for May 2025.
In May, the Positive dynamics for AN2 Therapeutics, Inc. shares will prevail with possible monthly volatility of 8.483% volatility is expected.
Pessimistic target level: 1.12
Optimistic target level: 1.23
Target values for the price of one AN2 Therapeutics share for Jun 2025.
In Jun, the Negative dynamics for AN2 Therapeutics, Inc. shares will prevail with possible monthly volatility of 10.902% volatility is expected.
Pessimistic target level: 1.10
Optimistic target level: 1.24
Target values for the price of one AN2 Therapeutics share for Jul 2025.
In Jul, the Positive dynamics for AN2 Therapeutics, Inc. shares will prevail with possible monthly volatility of 11.153% volatility is expected.
Pessimistic target level: 1.11
Optimistic target level: 1.25
Target values for the price of one AN2 Therapeutics share for Aug 2025.
In Aug, the Negative dynamics for AN2 Therapeutics, Inc. shares will prevail with possible monthly volatility of 7.874% volatility is expected.
Pessimistic target level: 1.03
Optimistic target level: 1.12
Target values for the price of one AN2 Therapeutics share for Sep 2025.
In Sep, the Negative dynamics for AN2 Therapeutics, Inc. shares will prevail with possible monthly volatility of 9.264% volatility is expected.
Pessimistic target level: 1.01
Optimistic target level: 1.11
Target values for the price of one AN2 Therapeutics share for Oct 2025.
In Oct, the Negative dynamics for AN2 Therapeutics, Inc. shares will prevail with possible monthly volatility of 10.482% volatility is expected.
Pessimistic target level: 0.98
Optimistic target level: 1.10
Target values for the price of one AN2 Therapeutics share for Nov 2025.
In Nov, the Positive dynamics for AN2 Therapeutics, Inc. shares will prevail with possible monthly volatility of 9.721% volatility is expected.
Pessimistic target level: 1.03
Optimistic target level: 1.14
Target values for the price of one AN2 Therapeutics share for Dec 2025.
In Dec, the Negative dynamics for AN2 Therapeutics, Inc. shares will prevail with possible monthly volatility of 8.124% volatility is expected.
Pessimistic target level: 1.02
Optimistic target level: 1.11
